75N95024Q00522

Submitted by fratecm on
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
Protein Production Biliverdin Reductase A
Contracting Office
National Institute on Drug Abuse (NIDA)

Contact Points

Primary Contract Specialist

Diedra
Prophet
diedra.prophet@nih.gov

Secondary Contracting Officer

Christine
Frate
christine.frate@nih.gov
NAICS Code Number
541380
This acquisition requires the production of biliverdin reductase A protein in the BVRA project for cocrystal structures of small molecule hits and leads with BVRA protein to assist in structure-based drug design. This work is being requested for the Early Translation Branch (ETB) at the National Center for Advancing Translational Sciences (NCATS).
Small Business Size Standard
$19 million
FPDS Classification Code
Q301
Estimated Period of Performance
Through March 2025
Delivery of Goods
N/A
Set-Aside Status
Not Set Aside
Competition Status
Non-Competitive
Vendor Name
Helix Biostructures LLC
Vendor Address
5225 Exploration Drive
Indianapolis, IN 46241
Single-Sole Source Determination
This acquisition requires previous experience in the handling compounds and proteins and obtaining X-ray structures of compounds within proteins. It is necessary that a scientist and/or technician with experience in kinase profiling will run kinase screening. Other requirements include: 1. Expression Construct Design & Plasmid Synthesis 2. Pilot E. coli BL21(DE3) star Test Expression (1L) 3. Pilot purification 4. Scale-up E. coli BL21(DE3) star Expression (8L) and 5. Scale-up Purification (4L). Helix Biostructures has extensive experience in these specific requirements and have met this specific requirement in the past. They have demonstrated the ability to handle similar proteins and generate these specific X-ray cocrystal structures. They recently succeeded in providing structures with 5 analogs in the HNMT project with ETB and continuity of that is critical. They are experienced with the workflow of handling compounds from NCATS.
Background/Description of Requirement

The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), which mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The Early Translational Branch (ETB) is tasked with identifying and developing novel small molecule leads for improving human health.

In pursuit of this goal, the Center has a strong internal trans-disciplinary team of scientists who continually discover novel small molecules to modulate molecular targets to identify novel treatment strategies.  As such, discovering lead molecules that could serve as starting points for therapeutic development for patients is a key part of discovery. At ETB we have initiated a project to develop small molecule inhibitors for Biliverdin Reductase as Therapy for Toxic Hyperbilirubinemia. We have screened our internal library and found hits. We require the production of BVRA protein and then crystallize within BVRA small molecule hits and leads to examine binding mode for structure guide drug design.

Specific Requirements include:

1. Expression Construct Design & Plasmid Synthesis
2. Pilot E. coli BL21(DE3) star Test Expression (1L)
3. Pilot purification
4. Scale-up E. coli BL21(DE3) star Expression (8L)
5. Scale-up Purification (4L)
6. Scientist and/or technician with experience in kinase profiling will run kinase screen

GOVERNMENT RESPONSIBILITIES
* NCATS ETB will send BVRA protein that is being used in biochemical assays for comparison.

DELIVERY OR DELIVERABLES:
*Electronic copy of report as indicated in reporting requirements.

DATA RIGHTS:
* FAR 52.227-17, Rights in Data- Special Works

PUBLICATIONS AND PUBLICITY:
*The contractor will not publish results of the work.

CONFIDENTIALITY OF INFORMATION:
*The contractor will keep the results of the acquisition confidential

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.